However, further experiments are required to evaluate if e.g. increasing the amount of the systemically applied MT-II or other routes of application could improve the observed neuroprotection after experimental stroke, before this promising protein could be tested in human stroke patients. The gene discussed is MT2A; the disease is stroke disorder.